⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL334917 | 0.82 | — | — | |
| Hydrochloric Acid SCHEMBL27994947 | 0.79 | TP53 (0.33) | — | |
| SCHEMBL93292 | 0.78 | — | — | |
| SCHEMBL10640209 | 0.75 | — | — | |
| SCHEMBL28943996 | 0.74 | — | — | |
| SCHEMBL1618347 | 0.74 | LMNA (0.39) | — | |
| SCHEMBL15455269 | 0.74 | LMNA (0.39) | — | |
| SCHEMBL1462040 | 0.73 | — | — | |
| SCHEMBL11294501 | 0.72 | LMNA (0.36) | — | |
| SCHEMBL21482196 | 0.72 | LMNA (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113185392-A | Synthesis method of dihydro jasmone | 安徽华业香料合肥有限公司 | 2021-07-30 | — | — | CN | claimed |
| CN-120136700-A | Synthesis method of L-acetoxy propionyl chloride | 连云港百裕生物科技有限公司 | 2025-06-13 | — | — | CN | disclosed |
| CN-113683650-A | Preparation method of beta-D- (1,4) -mannuronic acid oligosaccharide and intermediate thereof | 绿谷(上海)医药科技有限公司 | 2021-11-23 | — | — | CN | disclosed |
| CN-113185392-A | Synthesis method of dihydro jasmone | 安徽华业香料合肥有限公司 | 2021-07-30 | — | — | CN | disclosed |
| US-RE43899-E1 | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents | IMMUNOGEN INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-7303749-B1 | Immunoconjugate of a maytansine linked to a monoclonal antibody that binds to an antigen expressed by a cancer cell, and a taxane, an epothilone, a platinum compound, an epipodophyllotoxin, and/or a camptothecin | IMMUNOGEN INC. (US) | 2007-12-04 | — | — | US | disclosed |
| EP-0603160-A2 | Compositions for in-situ active compound assembly | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1994-06-22 | — | — | EP | disclosed |
| EP-0344990-B1 | Mitomycin derivatives and intermediates therefor | KYOWA HAKKO KOGYO KK (JP) | 1993-12-15 | — | — | EP | disclosed |
| US-5021423-A | Antibiotic, antitumor agent | KYOWA HAKKO KOGYO KABUSHIKI KAISHA (JP) | 1991-06-04 | — | — | US | disclosed |
| EP-0312543-A4 | _I(IN SITU) ACTIVE COMPOUND ASSEMBLY | — | 1990-12-27 | — | — | EP | disclosed |
| EP-0344990-A1 | Mitomycin derivatives and intermediates therefor | KYOWA HAKKO KOGYO KABUSHIKI KAISHA (JP) | 1989-12-06 | — | — | EP | disclosed |
| EP-0312543-A1 | $i(IN SITU) ACTIVE COMPOUND ASSEMBLY | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1989-04-26 | — | — | EP | disclosed |
| US-4812449-A | SYNTHESIS AT TARGET SITES, MICROENVIRONMENT | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1989-03-14 | — | — | US | disclosed |
| WO-1988000047-A1 | IN SITU ACTIVE COMPOUND ASSEMBLY | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1988-01-14 | — | — | WO | disclosed |